Sanofi Beats Wall Street Expectations, Touts Anti-Competitive Strategy on
Blockbuster Dupixent





 



BIG PHARMA EARNINGS WATCH: SANOFI

Sanofi Beats Wall Street Expectations, Touts Anti-Competitive Strategy on
Blockbuster Dupixent



Last week, Sanofi reported fourth quarter earnings that surpassed Wall Street
analysts’ expectations, increasing their guidance for 2026. The Big Pharma
company reported the blockbuster earnings after hiking drug prices for American
patients throughout 2025.



During Sanofi’s fourth quarter earnings call
<[link removed]>
, Houman Ashrafian, Head of Research and Development at Sanofi touted the
company’s extensive patent strategy around blockbuster eczema and asthma
treatment Dupixent, “We do expect Dupixent to be protected by its patents
beyond March 2031 in the U.S. That’s the reality. As you can imagine, lots of
innovation, lots of indications, and counting. These have been recognized by
multiple, and thank you for going through them, granted and to be granted
patents ranging from 2031 to 2035. We believe we have a very strong patent
portfolio, which we intend to vigorously defend. You’ll understand it’s too
early to speculate on specific dates or biosimilarity if and when patent fights
commence. We’ll be able to give you more details of what is being challenged
and where, but we feel we’re in a good place with multiple patents.”



Sanofi’s eagerness to game the patent system to block and delay competition to
Dupixent will be costly for American patients and taxpayers. For example,
Medicare Part D spending on specialty brand name drugs like Dupixent has
dramatically increased, while manufacturers have continued hiking prices.



According to a 2025 study
<[link removed]>
published in JAMA Dermatology, conducted by researchers affiliated with Harvard
Medical School and Brigham and Women’s Hospital, “inflation-adjusted Medicare
Part D spending increased… from $768 million in 2013 to $2.95 billion in 2022,”
with specialty prescription drugs, like Dupixent, driving “98.4% of this
growth, increasing from 30.8% of all dermatology drug spending in 2013 to 80.9%
in 2022, despite being only 2.9% of prescriptions.”



The report found that “[n]ew therapies approved after 2013 (Otezla, Cosentyx,
Taltz, Dupixent, Tremfya, Skyrizi, and Odomzo) accounted for 69.5% of all
spending growth,” and that “[a]verage inflation-adjusted prices per 30-day
prescription for specialty medications increased by 5.1% per year, from $3738
in 2013 to $5872 in 2022. In contrast, prices for nonspecialty medications
decreased by 5.3% annually relative to inflation.”



Get the full recap on Sanofi earnings here:

* Sanofi reported strong fourth quarter earnings that beat
<[link removed]>
Wall Street estimates.
* Sanofi’s Q4 sales grew 13.3 percent to $13.5 billion
<[link removed]>
, with total 2025 sales reaching$52 billion
<[link removed]>
.
* Sanofi’s blockbuster eczema and asthma treatment Dupixent generated $5
billion
<[link removed]>
in sales for Q4, exceeding forecasts.
* The French drugmaker said sales would rise by a high single-digit percentage

<[link removed]>
in 2026, with profit growing slightly faster.
Sanofi’s Q4 earnings follow price hikes across their portfolio recent years –
including at the start of 2026.

* In January, Sanofi raised the price of eight prescription drugs
<[link removed]>, including Dupixent, by five
percent.
* Throughout 2025, Sanofi hiked prices on 11 prescription drugs
<[link removed]>.
* In 2024, Sanofi increased the price of nine prescription drugs
<[link removed]>, including blockbuster drug
Dupixent, by six percent.
* Sanofi hiked prices on 20 prescription drugs
<[link removed]> in 2023.
* And Sanofi hiked prices on more than 11 prescription drugs
<[link removed]> in January 2022 – and engaged
in anadditional round <[link removed]> of price
hikes that summer.
Stay tuned as we continue to monitor fourth quarter earnings calls from brand
name drug companies in the coming weeks.



Read more on Q4 earnings from Johnson & Johnson HERE
<[link removed]>.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>